Updates are available Correction dated 2021-01-20
Click to view Correction: https://doi.org/10.1007/s00424-021-02519-0
-
Authors
Lahiri, Satadru K. https://orcid.org/0000-0001-9502-1530
Aguilar-Sanchez, Yuriana https://orcid.org/0000-0002-5516-8877
Wehrens, Xander H. T. https://orcid.org/0000-0001-5044-672X
-
Funding
Funding for this research was provided by:
National Heart, Lung, and Blood Institute (R01-HL089598, R01-HL091947, R01-HL117641, R01-HL147108)
- License Information
-
More Information
Article History
Received: 5 November 2020
Revised: 1 December 2020
Accepted: 9 December 2020
First Online: 5 January 2021
Change Date: 20 January 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s00424-021-02519-0
Compliance with ethical standards
:
: XHTW is a founding partner of Elex Biotech, a start-up company that developed drug molecules to target ryanodine receptors for treatment of cardiac arrhythmias. Other authors have no conflicts related to this study.
: N/A
: N/A
: The authors give consent for the publication of this manuscript.
: N/A
